APAC Emerging Biopharma Data
Overview
Tracks more than 150 upcoming facilities established since 2020 and over 150 recently founded emerging biotech companies founded since 2017. It’s a 2-in 1 tracker that brings unique data on emerging biopharma facilities and companies that are gaining a lot of traction in the biopharma industry. The data and companies included in this tracker is covered across 11 APAC countries including China, South-Korea, Japan, India, South-East Asia countries, Taiwan and Australia among others.
APAC Emerging Biopharma Data showcases the key information on emerging biologics manufacturing facilities and companies based on over 50 metrics including biologics products in development, list of technology/service partners, investors, upstream and downstream processing technologies, regulatory compliance followed by facilities, ongoing and completed projects, platform technology, company plans and updates, funding details, USP of company and partnership requirements and many other parameters. The complete list of parameters for both emerging facilities and companies’ information are mentioned in further section.
The data is underpinned by user-friendly visuals to allow users to filter through data by emerging company, manufacturing facility specialisation, company establishment year, product type, scale of operation, expression system and other filters.
Pick the right plan!
From evolving customer expectations and emerging technologies to more nimble companies entering industries, businesses today are more at risk for disruption than ever before.
6 Months
$3,640
- Access for 6 months
- Single user
- Monthly Updates
1 Year
$6,530
- Access for 1 year
- Single User
- Monthly Updates
Key Emerging Biopharma Parameters
- Biotech Name
- Spin-Off/Independent
- Company Status
- Company Type
- Founded Year
- Country
- Website
- Product Type
- Phases of Development
- Traction Metrics
- Company Description
- Products in Pipelines & Projects
- Team Size
- Funding Details
- Investors
- Platform Technology
- Process & Capabilities
- Bioprocessing Technology Details
- Expression System
- Regulatory Compliance & Approvals
- Future Plans
- Partnerships & Collaborations
Key Manufacturing Parameters
- Facility Name
- Facility Type
- Establishment Year
- Country
- Products Manufactured
- Scale of Operation
- USP of Facility
- Facility Specialization
- Facility Highlights
- Capabilities & Process
- Capacity Details
- Facility Size
- Manufacturing Technology
- Expression System
- Bioreactor Type
- Technology & Service Providers
- Ongoing Projects
- Upstream Processing Technology
- Downstream Processing Technology
- Facility Operation
- Drug Product
- Regulatory Approval & Compliance
- Expansion Plans and Other Updates
- Partnerships
- Funding Details & Stage
- Notable Investors
- Partnership Requirements
Regions Coverage
Australia, China, Hong Kong, India, Japan, Korea, Malaysia, Vietnam, Singapore, Taiwan, Thailand
Product Types Covered
Biologics
Cell Therapy
Gene Therapy
Vaccines
How These Data Will Benefit?
It tracks over 300 emerging biopharma companies and their facilities that are driving a major section of innovation and development in the biopharma industry. These companies are changing the landscape of biologics development by contributing to the innovative products and industry pipelines. Emerging Biopharma companies are highly focused on subject matter expertise and heavily rely on service partners to speed drug access to clinics and market. These companies are developing more than 90% of next-generation biotherapeutics, which include cell and gene therapies.
Through this data IMAPAC aims to provide an in-depth overview of the current and upcoming biotech companies that are gaining huge traction in the APAC biopharma industry. It will help you track new manufacturing facility that are producing different biological products in clinical and commercial scale through real-time insights. Keep track of new players in the market, their partners, funding deals, manufacturers, suppliers. Identify any opportunities for collaboration or investments for development or manufacturing of biologics in the Asia-Pacific region.
Data Methodology
The data in this tracker is researched and validated using primary and secondary research. The data is collected through multiple scientific and non-scientific sources including live discussions with experts through IMAPAC’s events and research reports, survey polls, company websites, press releases, publicly available information, regulatory database and many more.
We have a database of key decision makers from the biopharma, big pharma and CMOs across the region. We host industry surveys with leaders of Biopharma and CMOs, and host primary interviews with Heads of R&D, Manufacturing, Process Development Heads and multiple stakeholders in the companies to gather data as well as validate that data using our primary research analysts.
Throughout the year, we keep in touch with the KOLs through telephonic Conversation, with Q&A sessions with high profile biopharma professionals, for example CSO/CTO profiles. Apart from telephonic conversations, we send a list of questions which these experts fill in detail and send back to us.
We have dedicated analysts who gather data. The data included in the tracker is validated through primary research (interviews, phone calls) with stakeholders which is then validated by IMAPAC’s research analysts to ensure the accuracy of the data.
Key Questions Answered
- How many emerging biopharma companies are based in Asia-Pacific region?
- Where are these emerging companies set up across Asia?
- What is the unique traction feature of emerging biopharma?
- Which biologics are developed by emerging biopharma companies?
- What is the scale of operation at which these companies are working?
- What are some products in current projects?
- Highlights into company’s funding details and latest deals
- Who are the partners and notable investors supporting emerging biopharma companies?
- Who is the technology or service providers for new biotech companies?
- Which regulatory compliance guidelines and certifications are followed by emerging biopharma companies and new manufacturers?
- What is the capacity and batch size for production?
- Which specialization is offered by emerging CDMO/CMO in biopharma industry?
- Are emerging biopharma companies open for partnership or collaboration?
Data Sample
